Gill Eyre speaks to Pathology in Practice about company successes and how far Stago has developed since it first opened in the UK over 10 years ago.
The expansion of Stago in the UK is accelerating through ‘innovation, scientific excellence, partnership, quality of service and breadth of offering’, says Gill Eyre, who was recently appointed to the new role of sales and marketing manager to the Berkshire-based company.
She is quick to dispel any impression that might linger in the industry that Stago is too small a company compared to its competitors. Not only is the Stago group internationally recognised as a growing global company, but Stago UK has steadily increased its contribution to the NHS and today provides 20% of its haemostasis services.
“From the start, we have been respected for our scientific excellence. But Stago’s current haemostasis solutions have earned a valuable place on the NHS procurement agenda because of their technological excellence and reliability,” says Gill. “A Stago solution is often considered to best fit the market needs.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
Register
